Comparative Pharmacology
Head-to-head clinical analysis: CIS MDP versus IODOTOPE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIS MDP versus IODOTOPE.
CIS-MDP vs IODOTOPE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CIS-MDP (cisplatin) is a platinum-containing antineoplastic agent that forms intrastrand and interstrand DNA crosslinks, inhibiting DNA replication and transcription through binding to purine bases.
Iodine-131 is taken up by the thyroid gland and emits beta particles and gamma rays, causing destruction of thyroid tissue via radiation-induced cell death.
20 mCi (740 MBq) intravenous injection for bone scintigraphy; imaging performed 2-4 hours post-injection.
For thyroid ablation: 3.7-5.55 MBq (100-150 μCi) orally as a single dose. For hyperthyroidism: 185-555 MBq (5-15 mCi) orally as a single dose.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; clinically relevant for imaging timing and clearance from blood pool.
Terminal half-life is approximately 120-140 days for total body iodine, but the effective half-life for therapeutic use is 8-13 days due to biological turnover in the thyroid. For diagnostic use, effective half-life is 1-2 days.
Renal: 85-95% of administered dose excreted unchanged in urine within 24 hours; biliary/fecal: <5% eliminated via feces.
Primarily renal: >90% excreted in urine as iodide. Fecal excretion is negligible (<2%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical